All In Biotech

Drug Trial Radar · NCT06848348

Efficacy and Safety Study of Halneuron in the Treatment of Chemotherapy-Induced Neuropathic Pain

A Randomized, Double-Blind, Placebo Controlled, Multicenter Study With Optional Open-Label Extension to Evaluate the Efficacy and Safety Study of Halneuron in the Treatment of Chemotherapy-Induced Neuropathic Pain

Last checked: Nov 20, 2026Latest source record: Sep 16, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingRandomized with 240 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

240

Planned (sponsor's estimate)

Start

Feb 21, 2025

Primary completion

Dec 2026

Study completion Dec 2026

Sponsor

Lead sponsor
Dogwood Therapeutics Inc.Industry
Sponsor type
Industry
First posted
Feb 27, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

A randomized study to determine safety and efficacy of a series of subcutaneous (SC) injections of HAL in patients with CINP, compared to matching placebo injections. After that, subjects may have the option to enter an Open Label extension phase, where available, in which all subjects will receive Halneuron.

Conditions

  • Chemotherapy Induced Neuropathic Pain
  • Chemotherapy Induced Pain Neuropathy
  • Chemotherapy Induced Pain

Interventions

  • HalneuronDrug

    Halneuron for Subcutaneous Injection

  • PlaceboDrug

    Placebo for Subcutaneous Injection

  • Halneuron (Open Label Extension)Drug

    Halneuron for Subcutaneous Injection

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. NRS PainTime frame: From enrollment to end of study at 4 weeks
  2. Safety AssessmentsTime frame: From enrollment to end of study at 4 weeks

Locations

25 sites in 1 country. Site status is shown where the registry gives one.

  • Central Recruiting Site

    Sheffield, Alabama

  • Central Recruiting Site

    Glendale, Arizona

  • Central Recruiting Site

    Phoenix, Arizona

  • Central Recruiting Site

    Fair Oaks, California

  • Central Recruiting Site

    Fountain Valley, California

  • Central Recruiting Site

    Los Angeles, California

  • Central Recruiting Site

    Santa Rosa, California

  • Central Recruiting Site

    Wheat Ridge, Colorado

  • Central Recruiting Site

    Jacksonville, Florida

  • Central Recruiting Site

    Jacksonville, Florida

  • Central Recruiting Site

    Lakeland, Florida

  • Central Recruiting Site

    Orlando, Florida

  • Central Recruiting Site

    Port Charlotte, Florida

  • Central Recruiting Site

    Tampa, Florida

  • Central Recruiting Site

    Gurnee, Illinois

  • Central Recruiting Site

    Lake Charles, Louisiana

  • Central Recruiting Site

    Fenton, Missouri

  • Central Recruiting Site

    Las Vegas, Nevada

  • Central Recruiting Site

    Garden City, New York

  • Central Recruiting Site

    Williamsville, New York

  • Central Recruiting Site

    Winston-Salem, North Carolina

  • Central Recruiting Site

    Houston, Texas

  • Central Recruiting Site

    McAllen, Texas

  • Central Recruiting Site

    Salt Lake City, Utah

  • Central Recruiting Site

    Madison, Wisconsin

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.